0000000000093072

AUTHOR

L. Insalaco

showing 25 related works from this author

Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cance…

2021

Background: The addition of PD-L1 inhibitors to platinum-based chemotherapy (CT) has newly received United States Food and Drug Administration (FDA) approval in extensive stage-small cell lung cancer (ES-SCLC). PD-1 agents similarly improved survival rates, even if not yet supported by international regulatory agencies. The current work aims to assess different efficacy and safety profiles among chemoimmunotherapy plus immuno-oncology (CT+IO) approaches according to different immune checkpoint inhibitor (ICI) subtypes. Material & Methods: We included in our meta-analysis six first-line randomised controlled trials (RCTs) comparing the association of single-agent ICI with CT versus CT al…

0301 basic medicineOncologymedicine.medical_specialtyImmunotherapy for Lung Cancer: Progress Opportunities and Challengesmedicine.medical_treatmentCellFood and drug administration03 medical and health sciences0302 clinical medicineInternal medicinemedicinechemo-immunotherapy ES-SCLC indirect comparison meta-analysis PD-L1/PD-1 inhibitorsChemo immunotherapyRC254-282ChemotherapyLungbusiness.industryPD-L1/PD-1 inhibitorsNeoplasms. Tumors. Oncology. Including cancer and carcinogensIndirect comparison030104 developmental biologymedicine.anatomical_structureOncologyindirect comparison030220 oncology & carcinogenesisMeta-analysischemo-immunotherapybusinessExtensive-stage small cell lung cancerES-SCLCMeta-AnalysisTherapeutic Advances in Medical Oncology
researchProduct

79 VUS VARIANTS IN BRCA GENES OF HEREDITARY BREAST/OVARIAN CANCER

2010

OncologyBreast ovarian cancermedicine.medical_specialtyOncologybusiness.industryInternal medicinemedicineRadiology Nuclear Medicine and imagingGeneral MedicinebusinessBrca genesCancer Treatment Reviews
researchProduct

1281P The prognostic impact of tissue tumour mutational burden (TMB) in the first-line treatment of advanced non-oncogene addicted non-small cell lun…

2020

Oncologymedicine.medical_specialtyOncogenebusiness.industrynon-small cell lung cancer (NSCLC)Hematologymedicine.diseaselaw.inventionFirst line treatmentOncologyRandomized controlled triallawInternal medicineMeta-analysismedicinebusinessAnnals of Oncology
researchProduct

KRAS and BRAF as prognostic biomarkers in patients undergoing surgical resection of colorectal cancer liver metastasis: A systematic review and meta-…

2016

3565Background: Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of li...

OncologySurgical resectionCancer Researchmedicine.medical_specialtyendocrine system diseasesColorectal cancerbusiness.industrymedicine.diseasemedicine.disease_causedigestive system diseasesMetastasisClinical trialOncologyInternal medicineMeta-analysismedicineIn patientKRASbusinessSurgical treatmentneoplasmsJournal of Clinical Oncology
researchProduct

P33.15 TMB in the First-Line Setting of NSCLC: A Systematic Review with Indirect Comparisons Between PD-1 and PD-L1 Inhibitors

2021

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtyOncologybiologybusiness.industryPD-L1First lineInternal medicinemedicinebiology.proteinbusinessJournal of Thoracic Oncology
researchProduct

P07.02 Detection of Molecular Residual Disease (MRD) using ctDNA in NSCLC: A Systematic Review and Meta-Analysis

2021

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtyOncologybusiness.industryInternal medicineMeta-analysismedicineDiseaseResidualbusinessJournal of Thoracic Oncology
researchProduct

Aurora-A Transcriptional Silencing and Vincristine Treatment Show a Synergistic Effect in Human Tumor Cells

2008

Aurora-A is a centrosome-associated serine/threonine kinase that is overexpressed in multiple types of human tumors. Primarily, Aurora-A functions in centrosome maturation and mitotic spindle assembly. Overexpression of Aurora-A induces centrosome amplification and G 2 /M cell cycle progression. Recently, it was observed that overexpression of Aurora-A renders cells resistant to cisplatin (CDDP)-, etoposide-, and paclitaxel-induced apoptosis.Our results indicate that already in initial stages of cancer progression Aurora-A overexpression could have a major role in inducing supernumerary centrosomes and aneuploidy, as shown by immunohistochemistry on tissue sections from various stages of hu…

Cancer ResearchPathologymedicine.medical_specialtyTranscription GeneticApoptosismacromolecular substancesProtein Serine-Threonine KinasesBiologyTransfectionPLK1Aurora KinasesRNA interferenceCell Line TumormedicineHumansGene silencingGene SilencingRNA Small InterferingMitotic catastropheCentrosomeCisplatinCarcinomaCell CycleDrug SynergismAuroraA/stk15centrosome amplificationAneuploidy CINGeneral MedicineCell cycleAneuploidyAntineoplastic Agents PhytogenicGene Expression Regulation NeoplasticSettore BIO/18 - Geneticaenzymes and coenzymes (carbohydrates)OncologyVincristineCentrosomeColonic Neoplasmsembryonic structuresCancer cellCancer researchbiological phenomena cell phenomena and immunityHeLa Cellsmedicine.drugOncology Research Featuring Preclinical and Clinical Cancer Therapeutics
researchProduct

P48.10 Chemo-Immunotherapy in the Frontline of Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Indirect Comparisons

2021

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtyOncologybusiness.industryInternal medicineMedicinebusinessExtensive-stage small cell lung cancerChemo immunotherapyJournal of Thoracic Oncology
researchProduct

Vulvar and Vaginal Cancers

2021

Vulvar cancer and vaginal cancer are relatively rare tumors, typically affecting elder women, although they still represent the fourth and fifth, respectively, most common cancers in the gynecologic oncology field. Treatment of the early stages includes surgery and radiotherapy (external beam radiotherapy and brachytherapy). The sentinel lymph node sampling procedure is becoming the new standard of care in vulvar cancer. Chemotherapy has a role in combination with radiotherapy for the locoregional management or as palliative therapy for stage IV patients.

ChemotherapyVaginal cancermedicine.medical_specialtybusiness.industrymedicine.medical_treatmentBrachytherapySentinel lymph nodeGynecologic oncologyVulvar cancermedicine.diseaseRadiation therapymedicineExternal beam radiotherapyRadiologybusiness
researchProduct

The effects of LIPUS on ctDNA release in the medium of NSCLC cell lines

2017

Oncologybusiness.industryCell cultureNsclc cellCancer researchMedicineHematologybusinessAnnals of Oncology
researchProduct

Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?

2015

Microtubules are dynamic and structural cellular components involved in several cell functions, including cell shape, motility, and intracellular trafficking. In proliferating cells, they are essential components in the division process through the formation of the mitotic spindle. As a result of these functions, tubulin and microtubules are targets for anticancer agents. Microtubule-targeting agents can be divided into two groups: microtubule-stabilizing, and microtubule-destabilizing agents. The former bind to the tubulin polymer and stabilize microtubules, while the latter bind to the tubulin dimers and destabilize microtubules. Alteration of tubulin-microtubule equilibrium determines th…

Cancer ResearchEpothilonesSettore MED/06 - Oncologia MedicaOmbrabulin2734Antineoplastic AgentsReview ArticleMicrotubulesPathology and Forensic Medicinechemistry.chemical_compoundMicrotubuleNeoplasmsHumansRC254-282QH573-671biologyNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancer Research; Molecular Medicine; 2734; Cell BiologyCell BiologyGeneral MedicineDiscodermolideCell cycleCell biologySpindle apparatusTubulinchemistrybiology.proteinMolecular MedicineCytologyIntracellularAnalytical Cellular Pathology
researchProduct

Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma

2021

The molecular pathways which promote lung cancer cell features have been broadly explored, leading to significant improvement in prognostic and diagnostic strategies. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have dramatically altered the treatment approach for patients with metastatic non-small cell lung cancer (NSCLC). Latest investigations by using next-generation sequencing (NGS) have shown that other oncogenic driver mutations, believed mutually exclusive for decades, could coexist in EGFR-mutated NSCLC patients. However, the exact clinical and pathological role of concomitant genomic aberrations needs to be investigated. In this systematic review, we ai…

0301 basic medicineEGFRNSCLC03 medical and health sciences0302 clinical medicinesystematic reviewPathologyRB1-214MedicineEpidermal growth factor receptorLung cancerPathologicalbiologybusiness.industrymedicine.diseaserespiratory tract diseasesconcurrent genomic alterationCritical appraisal030104 developmental biologyLung cancer cellconcurrent genomic alterationsNGS030220 oncology & carcinogenesisConcomitantCancer researchbiology.proteinNon small cellbusinessTyrosine kinase<i>EGFR</i>Journal of Molecular Pathology
researchProduct

The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-an…

2016

OncologySurgical resectionmedicine.medical_specialtybusiness.industryColorectal cancerHematologymedicine.diseasemedicine.disease_causeMetastasisOncologyMeta-analysisInternal medicineMedicineIn patientKRASbusinessAnnals of Oncology
researchProduct

1818P Body mass index (BMI) is not a cancer risk factor for BRCA1/2 carriers: A systematic review and meta-analysis of case-control studies

2021

Oncologymedicine.medical_specialtyText miningOncologybusiness.industryMeta-analysisInternal medicineCase-control studymedicineHematologyCancer risk factorbusinessBody mass indexAnnals of Oncology
researchProduct

Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?

2016

// Daniele Fanale 1, * , Valeria Amodeo 1, * , Viviana Bazan 1, * , Lavinia Insalaco 1 , Lorena Incorvaia 1 , Nadia Barraco 1 , Marta Castiglia 1 , Sergio Rizzo 1 , Daniele Santini 2 , Antonio Giordano 3 , Sergio Castorina 4, 5, # , Antonio Russo 1, # 1 Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy 2 University Campus Bio-Medico, Department of Medical Oncology, Rome, Italy 3 Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA 4 Fondazione Mediterranea “G.B. Morgagni”, Catania, Italy 5 Department of Biomedic…

0301 basic medicineAntineoplastic AgentsBreast NeoplasmsBioinformatics03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancermicroRNAmedicineHumansZoledronic acidPI3K/AKT/mTOR pathwaybone metastasisBone Density Conservation AgentsDiphosphonatesMicroarray analysibusiness.industryGene Expression ProfilingImidazolesBone metastasisMicroRNA Expression Profilemedicine.diseaseActin cytoskeletonMolecular medicineBone metastasis; Breast cancer; Microarray analysis; miRNA expression profile; Zoledronic acid; Oncology030104 developmental biologyZoledronic acidOncologyBone metastasi030220 oncology & carcinogenesisMCF-7 CellsCancer researchmiRNA expression profilemicroarray analysisTranscriptomebusinessResearch Papermedicine.drug
researchProduct

33 EFFECT OF miR-21, miR-182 AND let-7i ON TSP-1 EXPRESSION IN COLON CANCER CELL LINE

2010

Oncologybusiness.industryColon cancer cell lineCancer researchMedicineRadiology Nuclear Medicine and imagingGeneral MedicinebusinessCancer Treatment Reviews
researchProduct

Endometrial and Cervical Cancers

2021

Uterine corpus and cervical cancers are showing, in the last decades, increasing incidence and mortality in industrialized and developing countries, respectively; on the other hand, innovative therapeutic strategies are emerging for the management of advanced gynecological malignancies. Risk factors and predisposing conditions are widely and continually studied; thus, prevention, through lifestyle correction and/or validated screening tests, could represent a promising tool to diagnose earlier and reduce mortality of uterine cancers. Herein, management of endometrial and cervical tumors from diagnosis to commonly applied standards of care and experimental frontiers are depicted so as to pro…

Oncologymedicine.medical_specialtyScreening testbusiness.industryIncidence (epidemiology)Endometriummedicine.diseasemedicine.anatomical_structureUterine corpusUterine cancerInternal medicinemedicinePersonalized medicinebusinessCervixChemoradiotherapy
researchProduct

LncRNA H19, HOTAIR and MALAT1 as prognostic molecular biomarkers in GIST

2017

MALAT1OncologyGiSTbusiness.industryCancer researchMedicineHOTAIRHematologybusinessMolecular biomarkersAnnals of Oncology
researchProduct

HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions

2013

Numerous microarray-based gene expression studies performed on several types of solid tumors revealed significant changes in key genes involved in progression and regulation of the cell cycle, including AURKA that is known to be overexpressed in many types of human malignancies. Tumor hypoxia is associated with poor prognosis in several cancer types, including breast cancer (BC). Since hypoxia is a condition that influences the expression of many genes involved in tumorigenesis, proliferation, and cell cycle regulation, we performed a microarray-based gene expression analysis in order to identify differentially expressed genes in BC cell lines exposed to hypoxia. This analysis showed that h…

Cancer ResearchSettore MED/06 - Oncologia MedicaDown-RegulationBreast NeoplasmsBiologymedicine.disease_causeAURKA Breast cancer Cell cycle HIF-1a HypoxiaCell Line TumorGene expressionTranscriptional regulationmedicineHumansPromoter Regions GeneticAurora Kinase ARegulation of gene expressionGene knockdownTumor hypoxiaCell cycleHypoxia (medical)Hypoxia-Inducible Factor 1 alpha SubunitMolecular biologyCell HypoxiaGene Expression Regulation NeoplasticOncologyGene Knockdown TechniquesCancer researchFemalemedicine.symptomCarcinogenesisBreast Cancer Research and Treatment
researchProduct

MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness?

2012

Recently, the hypothesis that colorectal tumors originate from a subpopulation of cells called ‘cancer stem cells' (CSCs) or tumor-initiating cells, which exhibit stem-like features, has been confirmed experimentally in various human cancers. Several studies have confirmed the existence of colorectal CSCs (CRCSCs) and have demonstrated that this rare cell population can be isolated by the expression of specific cell surface biomarkers. MicroRNAs (miRNAs) are a class of small non-coding RNAs, which are crucial for post-transcriptional regulation of gene expression and participate in a wide variety of biological functions, including development, cell proliferation, differentiation, metabolism…

Cancer ResearchSettore MED/06 - Oncologia MedicaPopulationReviewBiologymedicine.disease_causeBioinformaticsCSCstemnessCancer stem cellmicroRNAmedicineeducationMolecular BiologyRegulation of gene expressioneducation.field_of_studyCRC; CSCs; microRNAs; stemnessmicroRNACancermedicine.diseaseEmbryonic stem cellmicroRNAsCRCCancer researchCSCsStem cellCarcinogenesisOncogenesis
researchProduct

20P Is evaluation of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutational status on circulating tumour DNA (ctD…

2021

Kinasebusiness.industryProtein subunitAlpha (ethology)HematologyMolecular biologychemistry.chemical_compoundOncologyPhosphatidylinositol 45-bisphosphatechemistryMutational statusMedicineLiquid biopsybusinessDNAAnnals of Oncology
researchProduct

Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer

2018

The identification of tumor “oncogenic drivers” and the subsequent development of targeted therapy represented a milestone in the treatment of lung cancer over the last years. Tumor genotyping has been incorporated into therapeutic decision making of advanced non-small cell lung cancer (NSCLC) since has become clear that individuals with actionable molecular alterations receiving a matched targeted agent certainly live longer and better. The recent understanding of biological mechanisms underlying cancer immune evasion has allowed the development of a new class of immunomodulatory agents which are able to reactivate host immune-response, offering the potential for long-term disease control …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtycombinationsoncogene driversmedicine.medical_treatmentnon-small cell lung cancer (NSCLC)Treatment of lung cancerReview Articleoncogene driverTargeted therapyTargeted therapy03 medical and health sciencesInternal medicinemedicineRadiology Nuclear Medicine and imagingLung cancercombinationOncogenebusiness.industryCancerImmunotherapymedicine.diseaseClinical trialnon-small cell lung cancer (NSCLC)030104 developmental biologyOncologyimmunotherapybusiness
researchProduct

Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells

2012

Zoledronic acid (ZOL) is the most potent nitrogen-containing bisphosphonate (N-BPs) that strongly binds to bone mineral and acts as a powerful inhibitor of bone resorption, already clinically available for the treatment of patients with osteolytic metastases. Recent data also suggest that ZOL, used in breast cancer, may provide more than just supportive care modifying the course of the disease, though the possible molecular mechanism of action is still unclear. As breast cancer is one of the primary tumours with high propensity to metastasize to the bone, we investigated, for the first time, differential gene expression profile on Michigan Cancer Foundation-7 (MCF-7) breast cancer cells tre…

medicine.medical_specialtyAngiogenesismedicine.medical_treatmentBlotting WesternAngiogenesis InhibitorsAntineoplastic AgentsBreast NeoplasmsBiologyReal-Time Polymerase Chain ReactionZoledronic AcidZOL FN1 TGF-b1 THBS-1 invasion breast cancerBone resorptionThrombospondin 1Transforming Growth Factor beta1breast cancerBreast cancerTGF-β1Internal medicineThrombospondin 1medicineHumansBone ResorptionCell ProliferationMatrigelDiphosphonatesFN1Gene Expression ProfilingImidazolesCancerOriginal ArticlesCell BiologyZOLBisphosphonateMicroarray Analysisinvasionmedicine.diseaseFibronectinsUp-RegulationGene Expression Regulation NeoplasticEndocrinologyZoledronic acidTHBS-1MCF-7 CellsCancer researchMolecular MedicineFemalemedicine.drug
researchProduct

Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers

2015

Background: Long Non-coding RNAs (lncRNA) are emerging as essential regulators of genetic and epigenetic networks, and their deregulation may underlie complex diseases, such as carcinogenesis. Several studies have described lncRNAs alterations in patients with solid tumors. In particular, in Gastrointestinal Stromal Tumors (GIST), upregulation of HOTAIR has been associated with aggressiveness, metastasis, and poor patients’ survival. In order to gain more detailed insight on the molecular role of lncRNAs in GIST, we analyzed in vivo the expression levels of lncRNAs H19 and MALAT1 in surgically resected patients. Material and Methods: The expression of the lnc-RNAs H19 and MALAT1 was evaluat…

Long non coding RNAs Gastrointestinal Stromal Tumors prognostic/predictive biomarkers
researchProduct

EFFECT OF miR-21, miR-182 AND let-7i ON TSP-1 EXPRESSION IN COLON CANCER CELL LINE

2010

Background: MicroRNAs (miRNAs) are small non-coding RNAs that regulate the expression of different genes, including genes involved in cancer progression, angiogenesis and metastasis. Thrombospondin-1 (TSP-1) has been shown to contrast angiogenesis in vivo. TSP-1 expression levels are inversely correlated with tumor vascularity and metastasis in colon cancer. Bio-informatic statistical analysis indicated that TSP-1 is hypothetical target of miR-21, miR-182, overexpressed in CRC, and let-7i which expression is down-regulated in this tumor. In this work we investigated whether TSP-1 expression could be regulated by miR-21, mir-182 and let-7i in HT29 colon cancer cell line. Methods: To investig…

Colon cancer cell line microRNA
researchProduct